Reports on foslevodopa+foscarbidopa as a therapeutic approach for advanced Parkinson disease aimed at improving symptomatic dopaminergic replacement.

Clinically relevant for optimizing levodopa delivery and reducing motor fluctuations (high translational value), but offers limited mechanistic or disease‑modifying insight and evaluation is constrained by the missing abstract.